Timothy Rittman

List of Publications by Year
in descending order

63	3,463	186265	161849
papers	citations	28 h-index	54 g-index

78	78	78	5397
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study. Brain, 2022, 145, 340-348.	7.6	21
2	InÂVivo ¹⁸F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy. Journal of Nuclear Medicine, 2022, 63, 1052-1057.	5.0	9
3	Prediagnostic Progressive Supranuclear Palsy â€“ Insights from the UK Biobank. Parkinsonism and Related Disorders, 2022, 95, 59-64.	2.2	7
4	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimer's and Dementia, 2021, 17, 969-983.	0.8	31
5	In vivo PET imaging of neuroinflammation in familial frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 319-322.	1.9	21
6	Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants. Brain Communications, 2021, 3, fcab206.	3.3	12
7	Neuroinflammation predicts disease progression in progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 769-775.	1.9	40
8	In vivo coupling of dendritic complexity with presynaptic density in primary tauopathies. Neurobiology of Aging, 2021, 101, 187-198.	3.1	17
9	Synaptic density in carriers of C9orf72 mutations: a [¹¹C]UCBâ€‘J PET study. Annals of Clinical and Translational Neurology, 2021, 8, 1515-1523.	3.7	27
10	Progressive supranuclear palsy: diagnosis and management. Practical Neurology, 2021, 21, 376-383.	1.1	12
11	Coâ€Occurrence of Apathy and Impulsivity in Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2021, 8, 1225-1233.	1.5	6
12	Altered network stability in progressive supranuclear palsy. Neurobiology of Aging, 2021, 107, 109-117.	3.1	8
13	Altered structural connectivity networks in dementia with lewy bodies. Brain Imaging and Behavior, 2021, 15, 2445-2453.	2.1	8
14	Disease-related cortical thinning in presymptomatic granulin mutation carriers. NeuroImage: Clinical, 2021, 29, 102540.	2.7	8
15	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Servicesâ€”part 2 of 6. Alzheimer's Research and Therapy, 2021, 13, 169.	6.2	35
16	In vivo rate-determining steps of tau seed accumulation in Alzheimerâ€™s disease. Science Advances, 2021, 7, eabh1448.	10.3	70
17	Falls in Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2020, 7, 16-24.	1.5	16
18	Towards accurate and unbiased imaging-based differentiation of Parkinsonâ€™s disease, progressive supranuclear palsy and corticobasal syndrome. Brain Communications, 2020, 2, fcaa051.	3.3	14

#	Article	IF	Citations
19	Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy. Annals of Neurology, 2020, 88, 1194-1204.	5.3	38
20	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. Brain Communications, 2020, 2, .	3.3	20
21	Trajectory of apathy, cognition and neural correlates in the decades before symptoms in frontotemporal dementia. Alzheimer's and Dementia, 2020, 16, e041821.	0.8	0
22	Microglial activation and tau burden predict cognitive decline in Alzheimerâ€™s disease. Brain, 2020, 143, 1588-1602.	7.6	113
23	Neurological update: neuroimaging in dementia. Journal of Neurology, 2020, 267, 3429-3435.	3.6	11
24	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	2.4	26
25	Test Your Memory (TYM test): diagnostic evaluation of patients with non-Alzheimer dementias. Journal of Neurology, 2019, 266, 2546-2553.	3.6	8
26	Atomoxetine and citalopram alter brain network organization in Parkinsonâ€™s disease. Brain Communications, 2019, 1, fcz013.	3.3	10
27	Asymmetrical atrophy of thalamic subnuclei in Alzheimer's disease and amyloidâ€positive mild cognitive impairment is associated with key clinical features. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 690-699.	2.4	26
28	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	10.2	128
29	Test Your Memory (TYM) and Test Your Memory for Mild Cognitive Impairment (TYM-MCI): A Review and Update Including Results of Using the TYM Test in a General Neurology Clinic and Using a Telephone Version of the TYM Test. Diagnostics, 2019, 9, 116.	2.6	10
30	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. NeuroImage, 2019, 189, 645-654.	4.2	33
31	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	2.7	27
32	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiology of Aging, 2019, 77, 169-177.	3.1	47
33	Tau burden and the functional connectome in Alzheimerâ€™s disease and progressive supranuclear palsy. Brain, 2018, 141, 550-567.	7.6	190
34	InÂvivo coupling of tau pathology and cortical thinning in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 678-687.	2.4	24
35	Reply: Brain oscillations, inhibition and social inappropriateness in frontotemporal degeneration. Brain, 2018, 141, e74-e74.	7.6	1
36	Neurophysiological signatures of Alzheimerâ€™s disease and frontotemporal lobar degeneration: pathology versus phenotype. Brain, 2018, 141, 2500-2510.	7.6	60

#	Article	IF	Citations
37	Reorganization of cortical oscillatory dynamics underlying disinhibition in frontotemporal dementia. Brain, 2018, 141, 2486-2499.	7.6	64
38	Atomoxetine effects on attentional bias to drug-related cues in cocaine dependent individuals. Psychopharmacology, 2017, 234, 2289-2297.	3.1	16
39	[P1â€“029]: IN GENETIC FRONTOTEMPORAL DEMENTIA, FUNCTIONAL NETWORK EFFICIENCY IS MAINTAINED UNTIL THE ONSET OF SYMPTOMS: EVIDENCE FOR FUNCTIONAL RESILIENCE TO STRUCTURAL CHANGE. Alzheimer's and Dementia, 2017, 13, P244.	0.8	0
40	[P1â€“415]: IN GENETIC FRONTOTEMPORAL DEMENTIA, FUNCTIONAL NETWORK EFFICIENCY IS MAINTAINED UNTIL THE ONSET OF SYMPTOMS: EVIDENCE FOR FUNCTIONAL RESILIENCE TO STRUCTURAL CHANGE. Alzheimer's and Dementia, 2017, 13, P436.	0.8	0
41	Managing cognition in progressive supranuclear palsy. Neurodegenerative Disease Management, 2016, 6, 499-508.	2.2	32
42	Gene transcription profiles associated with inter-modular hubs and connection distance in human functional magnetic resonance imaging networks. Philosophical Transactions of the Royal Society B: Biological Sciences, 2016, 371, 20150362.	4.0	188
43	Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy. Neurobiology of Aging, 2016, 48, 153-160.	3.1	79
44	Adolescence is associated with genomically patterned consolidation of the hubs of the human brain connectome. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9105-9110.	7.1	415
45	Atomoxetine restores the response inhibition network in Parkinsonâ€™s disease. Brain, 2016, 139, 2235-2248.	7.6	76
46	Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinsonâ€™s disease. Brain, 2016, 139, 161-173.	7.6	88
47	Predicting beneficial effects of atomoxetine and citalopram on response inhibition in <scp>P</scp>arkinson's disease with clinical and neuroimaging measures. Human Brain Mapping, 2016, 37, 1026-1037.	3.6	60
48	Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinsonâ€™s Disease. Neuropsychopharmacology, 2016, 41, 2171-2177.	5.4	43
49	The basal ganglia in cognitive disorders. , 2016, , 69-80.		4
50	Improving response inhibition systems in frontotemporal dementia with citalopram. Brain, 2015, 138, 1961-1975.	7.6	71
51	Improving Response Inhibition in Parkinsonâ€™s Disease with Atomoxetine. Biological Psychiatry, 2015, 77, 740-748.	1.3	93
52	Multiple Modes of Impulsivity in Parkinson's Disease. PLoS ONE, 2014, 9, e85747.	2.5	116
53	The medial frontal-prefrontal network for altered awareness and control of action in corticobasal syndrome. Brain, 2014, 137, 208-220.	7.6	66
54	Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 925-929.	1.9	135

#	Article	IF	Citations
55	Selective serotonin reuptake inhibition modulates response inhibition in Parkinsonâ€™s disease. Brain, 2014, 137, 1145-1155.	7.6	113
56	Exploration of functional brain networks in neurodegenerative disease. Lancet, The, 2013, 381, S92.	13.7	1
57	Transcriptional data: a new gateway to drug repositioning?. Drug Discovery Today, 2013, 18, 350-357.	6.4	209
58	Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropharmacology, 2013, 64, 490-495.	4.1	121
59	The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 544-551.	1.9	94
60	Is referral to the neuro-oncology MDT safe?. British Journal of Neurosurgery, 2012, 26, 321-324.	0.8	10
61	T1-Weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. Movement Disorders, 2011, 26, 1633-1638.	3.9	158
62	Nutritional factors associated with survival following enteral tube feeding in patients with motor neurone disease. Journal of Human Nutrition and Dietetics, 2010, 23, 408-415.	2.5	41
63	Human papillomavirus infection in women who develop high-grade cervical intraepithelial neoplasia or cervical cancer: a caseâ€“control study in the UK. British Journal of Cancer, 2005, 92, 1794-1799.	6.4	7